Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis

Published:2018-07-13 Issue:8 Volume:19 Page:559-571
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Gallien S¹²^ORCID,Massetti M³,Flandre P⁴,Leleu H³,Descamps D⁵⁶,Lazaro E⁷⁸

Affiliation:

1. Henri Mondor University Hospital; Créteil France

2. University of Paris-Est Créteil Val de Marne Medical School; Créteil France

3. Public Health Expertise; Paris France

4. INSERM Sorbonne University; UPMC University Paris 06; UMR-S 1136; Pierre Louis Institute of Epidemiology and Public Health; Paris France

5. Bichat Claude Bernard University Hospital; Paris France

6. University Paris Diderot Medical School; Paris France

7. Bordeaux University Hospital; Bordeaux France

8. University of Bordeaux; Bordeaux France

Funder

Gilead Sciences

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hiv.12643/fullpdf

Reference51 articles.

1. European AIDS Clinical Society European Guidelines for treatment of HIV-positive adults in Europe 2017

2. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

3. WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach - Second edition 2016

4. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study;Clotet;Lancet,2014

5. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials;Sax;Lancet,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the Efficacy and Safety of a Doravirine-Based, Three-Drug Regimen in Treatment-Naïve HIV-1 Positive Adults: A Bayesian Network Meta-Analysis;Frontiers in Pharmacology;2022-04-20

2. Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis;Frontiers in Pharmacology;2021-07-21

3. Brief Report: Surveillance of Congenital Anomalies After Exposure to Raltegravir or Elvitegravir During Pregnancy in the United Kingdom and Ireland, 2008–2018;JAIDS Journal of Acquired Immune Deficiency Syndromes;2019-03-01